OncoSenX targets solid tumours with senolytics
Lifespan.io (LEAF) - 22-Oct-2019Phase 1 clinical trial starting early 2020
Join the club for FREE to access the whole archive and other member benefits.
CSO Oision Biotechnologies, co-founder of Oisin Oncology and Chair in Prostate Cancer Research at the University of Alberta
Dr. John Lewis the co-founder of Oisin Oncology and heads its cancer-fighting platform technology development and clinical research. Dr. Lewis also holds the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta. He is an Associate Professor in the Department of Oncology and chairs the Alberta Prostate Cancer Research Initiative. Dr. Lewis has also founded three Canadian biotechnology companies.
Visit website: https://www.oisinbio.com/#the-team
See also: Oisin Biotechnologies - Drug development company focused on the senolytic technology to fight age-related diseases
Details last updated 06-Nov-2019
Phase 1 clinical trial starting early 2020